Larvol Delta - AmMax-Bio-Announces-Oral-Presentation-of-Phase-2-Data-of-AMB05X-for-the-Treatment-of-Tenosynovial-Giant-Cell-Tumor-TGCT-at-the-2022-CTOS-Annual-Meeting

AMB-05X - AmMax

https://www.globenewswire.com/news-release/2022/11/18/2559064/0/en/AmMax-Bio-Announces-Oral-Presentation-of-Phase-2-Data-of-AMB-05X-for-the-Treatment-of-Tenosynovial-Giant-Cell-Tumor-TGCT-at-the-2022-CTOS-Annual-Meeting.html

Nov 18, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next